In recent years, patient-centric initiatives are becoming key factors among healthcare companies, as they are increasingly becoming aware of the fact that the key to growing business and improving customer health is to better focus on the needs and concerns of the patient, rather than attending to just the product approval. The objective behind patient-centric drug development and other associated initiatives is to involve patients and the healthcare community as partners in order to bring about a sense of ownership in the success of new medical treatments. (1,2) There are four core principles that frame the growing arsenal of patient centric initiatives: (3)
Adherence to the above principles facilitate patient-centric drug development to encourage the sharing of important information and drug development risk among a broader community of external partners e.g., academic and basic research groups, co-development sponsors, development operations alliances, and patient advocacy groups. (3)
A growing number of researchers are adapting to patient-centric initiatives across multiple studies, which can eventually be used while centrally monitoring and coordinating activities. This can further promote harmonization and can also better assist in communicating lessons learned from earlier implementations and from peer companies. Such activities can also help in deriving consensus metrics to evaluate the impact of various initiatives on organizational and study-level processes and performance. (3,4)
Return on investment (ROI) expectations are required to consider a reasonably long-term view. This is because researchers need enough time to collect experience with patient-centric initiatives, learn from mistakes while continuously processing their use. Ideally, target measures from multiple representative studies should be gathered two to three years prior to and after the implementation of initiatives. Stakeholders use some key implementation and ROI metrics to measure three broad areas, viz. reach; patient/study volunteer feedback; and performance. (3)
We feel that it is too early to conclude on this aspect, as there is inadequate data demonstrating the extent and impact of patient-centric initiatives, across the industry. Needless to mention that patient-centricity movement is certainly inspiring the drug development enterprise to challenge and transform the traditional drug development prototype by putting the patient at its core.
Become an Certified HEOR Professional – Enrol yourself here!